# ASCEND-7 (NCT02336451)

> A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

No report yet. It can be ordered.

- Drugs tested: ceritinib
- Indication: ALK-positive NSCLC metastatic to brain and/or leptomeninges

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02336451
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: ALK-positive Non-small Cell Lung Cancer
- Interventions: Ceritinib
- Enrollment: 156
- Primary outcome: Overall Response Rate (ORR) Per Investigator Assessment

## Indexed commentary on ASCEND-7 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ascend-7-nct02336451